Empagliflozin alters lipid metabolism in the myocardium and liver in a prediabetes model with severe dyslipidemia

• Main Authors: Denisa Miklankova (Author), Irena Markova (Author), Martina Hüttl (Author), Hana Malinska (Author)
• Formato: Libro
• Publicado: Frontiers Media S.A., 2024-07-01T00:00:00Z.
• Subjects: article
• Acceso en liña: Connect to this object online.

Background and aimsRecent studies suggest that empagliflozin reduces total and cardiovascular mortality in both diabetic and nondiabetic subjects. Although the exact mechanism is unclear, it is understood to positively affect myocardial energetics, including the metabolism of ketone bodies, lipids,...